Research powered investment banking
Home
Research
Companies
Themes
Top Picks
Transactions
Events
Redeye
At a Glance
Our Culture
Research & Ratings
Investor Services
Corporate Broking
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
Posts
Investor Scoring
sign in
Home
research
Companies
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Research & Ratings
Investor Services
Corporate Broking
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
community
Posts
Investor Scoring
  • POSTS
  • INVESTOR SCORING

Member profile

My Profile expand-item-icon-hover New Post

loparn

  • Blog posts

Immunicum - MERECA-utfallet i Q3 2019 är den stora triggern

LO
loparn

2019-02-03
0 comments

Immunicums immunförstärkare ilixadencel har en enormt stor och bred potential genom att kombineras med cancerläkemedel som synergistiskt motverkar tumörers egen immunsuppression av ilixadencel aktiver...

ExpreS2ion Biotech Holding - potential och riskspridning med prognosen positivt kassaflöde 2018

LO
loparn

2017-11-13
0 comments

ExpreS2ion Biotech Holding har en fantastisk långsiktig potential i det 50 %-ägda joint venture-bolaget AdaptVac som är vetenskapligt mycket välgrundad i forskning vid Köpenhamns Universitet om att på...

ExpreS2ion Biotech Holding

ExpreS2ion Biotech Holding har en mycket stor potential i sitt joint venture AdaptVac

LO
loparn

2017-10-27
0 comments

Ann-Cathrin Engwall, PhD i mokylärbiologi med immunologi och virologi som specialiteter, har gjort följande analys av ExpreS2ion Biotech Holdings joint venture AdaptVacs teknologiplattform som har en...

Tobii - sannolik långsiktig vinnare när eyetracking når volymmarknader

LO
loparn

2017-04-09
0 comments

Tobii har en imponerande historia av 16 års organisk tillväxt inom eyetracking och dominerar världsmarknaderna för kommunikationshjälpmedel och beteendestyrning genom de lönsamma affärsområdena Tobii...

Tobii

WntResearch will present "exiting" Phase I results November 6 in Boston

LO
loparn

2015-10-13
0 comments

The WntResearch drug candidate Foxy-5 has emerged as a possible new blockbuster in a novel cancer treatment concept targeting the lethal metastatic process. Phase I results for biomarkers will be pres...

WntResearch
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 61

Redeye community rules

The Redeye community members are responsible for their content. As a reader, you’re encouraged to critically analyze the content and do your own research. Before posting or commenting, please review our Rules & Guidelines

Top posts last week

  • Beowulf, en chans man inte får missa. Större rörelse att vänta. 2019-02-13 gruvspecialisten
  • Beowulfs värde med LKABs resultat som grund. Vi vidhåller tidigare värdering. Potentialen imponerar. 2019-02-18 gruvspecialisten
  • LUMITO 2019 års hetaste uppköpskandidat 2019-02-19 l.stein


Top authors last week

  • GR
    gruvspecialisten  
  • hansanalytic's avatar
    hansanalytic  
  • LS
    l.stein  
  • Office
  • Mäster Samuelsgatan 42, 10th floor
  • Box 7141, 103 87
  • Stockholm, Sweden
  • info@redeye.se
  • +46 (0)8 545 013 30
  • Services
  • Home
  • Research
  • Transactions
  • Events
  • Redeye
  • Community
  • Members Home
  • Premium
  • Legal
  • Terms and conditions (Swedish)
  • Terms of membership (Swedish)
  • Integrity Policy (Swedish)
  • Disclaimer (Swedish)
  • Governance
  • Follow
  • Twitter
  • Facebook
  • LinkedIn
  • Redeye
  • At a Glance
  • Our Culture
  • Research & Ratings
  • Investor Services
  • Corporate Broking
  • Corporate Finance
  • Newsroom
  • The Team
  • Careers
  • FAQ

© All rights reserved. Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2017